MX2021003906A - Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas. - Google Patents

Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.

Info

Publication number
MX2021003906A
MX2021003906A MX2021003906A MX2021003906A MX2021003906A MX 2021003906 A MX2021003906 A MX 2021003906A MX 2021003906 A MX2021003906 A MX 2021003906A MX 2021003906 A MX2021003906 A MX 2021003906A MX 2021003906 A MX2021003906 A MX 2021003906A
Authority
MX
Mexico
Prior art keywords
lukb
luka
lukab
staphylococcus aureus
therapeutic compositions
Prior art date
Application number
MX2021003906A
Other languages
English (en)
Inventor
Victor J Torres
Ashley L Dumont
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2021003906A publication Critical patent/MX2021003906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Abstract

En la presente se describe leucocidina de dos componentes de Staphylococcus aureus aislada y purificada, refereida aquí como LukAB, y sus componentes LukA y LukB, anticuerpos específicos para LukA, anticuerpos específicos para LukB, composiciones terapéuticas que contienen LukA y/o LukB, o anticuerpo anti-LukA y/o anti-LukBs, usos de las composiciones para tratar afecciones inflamatorias agudas o infección por S. aureus, métodos para identificar inhibidores de citotoxicidad mediada por LukAB de fagocitos humanos, y métodos para usar LukAB como un marcador para predecir la severidad de la infección por S. aureus.
MX2021003906A 2010-05-05 2012-11-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas. MX2021003906A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33155010P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
MX2021003906A true MX2021003906A (es) 2021-09-30

Family

ID=44902083

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015016666A MX364642B (es) 2010-05-05 2011-05-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2012012859A MX2012012859A (es) 2010-05-05 2011-05-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2019005156A MX2019005156A (es) 2010-05-05 2012-11-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2021003906A MX2021003906A (es) 2010-05-05 2012-11-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2015016666A MX364642B (es) 2010-05-05 2011-05-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2012012859A MX2012012859A (es) 2010-05-05 2011-05-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2019005156A MX2019005156A (es) 2010-05-05 2012-11-05 Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.

Country Status (21)

Country Link
US (5) US9783582B2 (es)
EP (4) EP4015523A1 (es)
JP (4) JP6031029B2 (es)
KR (3) KR102050078B1 (es)
CN (2) CN107286224A (es)
AU (5) AU2011247989C1 (es)
BR (1) BR112012029521A2 (es)
CA (2) CA3088918A1 (es)
DK (1) DK3444268T3 (es)
ES (2) ES2605476T3 (es)
HR (1) HRP20220068T1 (es)
HU (1) HUE058787T2 (es)
IL (2) IL222874B (es)
LT (1) LT3444268T (es)
MX (4) MX364642B (es)
MY (1) MY165618A (es)
PL (1) PL3444268T3 (es)
RU (2) RU2677140C1 (es)
SI (1) SI3444268T1 (es)
WO (1) WO2011140337A2 (es)
ZA (4) ZA201208455B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102050078B1 (ko) 2010-05-05 2019-11-28 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도
LT3403669T (lt) * 2011-06-19 2020-10-12 New York University Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai
ES2546105T3 (es) 2012-04-17 2015-09-18 Arsanis Biosciences Gmbh Anticuerpo de reacción cruzada contra Staphylococcus aureus
CN104428000A (zh) * 2012-05-02 2015-03-18 纽约大学 治疗和预防金黄色葡萄球菌感染和相关病状的方法
KR101826538B1 (ko) * 2012-05-30 2018-02-07 현대자동차 주식회사 차량용 글래스 몰딩 부착 장치 및 그 방법
US20160108106A1 (en) * 2013-05-21 2016-04-21 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
US10301378B2 (en) * 2013-06-18 2019-05-28 New York University Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets
BR112016008275A2 (pt) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
WO2015091935A2 (en) * 2013-12-19 2015-06-25 Arsanis Biosciences Gmbh Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
WO2018165089A1 (en) * 2017-03-06 2018-09-13 Vanderbilt University Human monoclonal antibodies to staphylococcus aureus lukab toxin
WO2018232014A1 (en) * 2017-06-13 2018-12-20 Integrated Biotherapeutics, Inc. Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
CA3115765A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
AU2020358862A1 (en) 2019-10-02 2022-04-14 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
IL301406A (en) * 2020-09-28 2023-05-01 Janssen Pharmaceuticals Inc Variant polypeptides of STAPHYLOCOCCUS AUREUS LUKA and LUKB and vaccine compositions
IL307178A (en) * 2021-04-02 2023-11-01 Janssen Pharmaceuticals Inc Vaccine components against Staphylococcus aureus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US300A (en) 1837-07-29 Machine foe spinning woolen roving
US400A (en) 1837-09-25 Mode of causing puppet valves to work lights
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
WO2000015238A1 (en) 1998-09-14 2000-03-23 Nabi COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP4416664B2 (ja) 2002-05-03 2010-02-17 マサチューセッツ・インスティテュート・オブ・テクノロジー Δ４，５グリクロニダーゼおよびその使用
US20090074755A1 (en) 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
CN100485038C (zh) * 2005-09-13 2009-05-06 四川大学华西医院 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
AU2007221321B2 (en) * 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
NZ597046A (en) * 2006-06-12 2014-01-31 Glaxosmithkline Biolog Sa Use of alpha-toxin for treating and preventing staphylococcus infections
CN101535811B (zh) 2006-10-18 2016-05-04 生物梅里埃公司 用于体外诊断产pvl金黄色葡萄球菌的方法
GB0624340D0 (en) * 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2215269B1 (en) 2007-10-15 2017-12-13 Admedus Vaccines Pty Limited Construct system and uses therefor
CN101182350A (zh) * 2007-11-02 2008-05-21 山东省农业科学院奶牛研究中心 金黄色葡萄球菌α-溶血素及其编码序列
WO2009111177A2 (en) * 2008-03-05 2009-09-11 Mount Sinai School Of Medicine Of New York University Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
SI2510947T1 (sl) * 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
KR102050078B1 (ko) 2010-05-05 2019-11-28 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도

Also Published As

Publication number Publication date
ZA201802995B (en) 2020-12-23
MX364642B (es) 2019-05-03
KR101933226B1 (ko) 2018-12-28
AU2019222824A1 (en) 2019-09-19
US20230295248A1 (en) 2023-09-21
RU2677140C1 (ru) 2019-01-15
JP7001661B2 (ja) 2022-02-21
KR20130060230A (ko) 2013-06-07
MX2012012859A (es) 2013-03-20
RU2018146933A (ru) 2020-06-29
MY165618A (en) 2018-04-18
KR102050078B1 (ko) 2019-11-28
RU2012152086A (ru) 2014-06-10
LT3444268T (lt) 2022-04-11
CN103025352A (zh) 2013-04-03
RU2644237C2 (ru) 2018-02-08
IL222874A0 (en) 2012-12-31
JP2020055835A (ja) 2020-04-09
ZA201603107B (en) 2018-09-26
AU2011247989A1 (en) 2012-12-06
AU2015200901B2 (en) 2016-12-15
IL222874B (en) 2020-05-31
SI3444268T1 (sl) 2022-05-31
US8431687B2 (en) 2013-04-30
JP2017048206A (ja) 2017-03-09
KR20180137612A (ko) 2018-12-27
MX2019005156A (es) 2019-08-05
ZA202002470B (en) 2022-12-21
ES2605476T3 (es) 2017-03-14
EP2566519A4 (en) 2014-01-15
JP2013531620A (ja) 2013-08-08
BR112012029521A2 (pt) 2018-03-06
US11584782B2 (en) 2023-02-21
JP2018076324A (ja) 2018-05-17
AU2011247989B2 (en) 2014-11-27
KR20190133290A (ko) 2019-12-02
AU2015200901A1 (en) 2015-03-12
US10316067B2 (en) 2019-06-11
AU2021236457A1 (en) 2021-10-14
AU2011247989C1 (en) 2015-05-14
HUE058787T2 (hu) 2022-09-28
CA2798355A1 (en) 2011-11-10
PL3444268T3 (pl) 2022-04-19
US20190330284A1 (en) 2019-10-31
AU2016262661B2 (en) 2019-07-25
CN103025352B (zh) 2017-07-11
CN107286224A (zh) 2017-10-24
CA3088918A1 (en) 2011-11-10
HRP20220068T1 (hr) 2022-04-15
US9783582B2 (en) 2017-10-10
JP6253742B2 (ja) 2017-12-27
DK3444268T3 (da) 2022-01-31
US20130095115A1 (en) 2013-04-18
EP2566519B1 (en) 2016-09-07
EP3444268B1 (en) 2021-12-15
JP6031029B2 (ja) 2016-11-24
EP4015523A1 (en) 2022-06-22
EP3444268A1 (en) 2019-02-20
ES2904314T3 (es) 2022-04-04
EP3121191B1 (en) 2018-09-26
WO2011140337A3 (en) 2012-03-15
EP2566519A2 (en) 2013-03-13
EP3121191A1 (en) 2017-01-25
US20180099998A1 (en) 2018-04-12
IL274109A (en) 2020-06-30
ZA201208455B (en) 2016-07-27
CA2798355C (en) 2020-09-15
US20110274693A1 (en) 2011-11-10
JP6678634B2 (ja) 2020-04-08
AU2016262661A1 (en) 2016-12-08
WO2011140337A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
MX2021003906A (es) Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
IN2014CN04907A (es)
EP3470526A3 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
EA201201648A1 (ru) Стимуляторы sgc
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
EA201200486A1 (ru) Лечение онкологических заболеваний
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
IN2012DN03883A (es)
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
TW201611725A (en) Pest control agent
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
IN2015DN01230A (en) Pyrrolopyrazoles as n type calcium channel blockers
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
MX2012002299A (es) Uso de cetoenoles ciclicos contra bacterias fitopatogenas.